David B. Beck

Last updated
David B. Beck
David Benjamin Beck 2021.png
Born
David Benjamin Beck

New Haven, Connecticut, USA
NationalityAmerican
Alma mater
Known forVEXAS Syndrome, Autoinflammatory Disease, Rare Genetic Disease
Scientific career
FieldsClinical Genetics
Institutions
Doctoral advisor Danny Reinberg
Website https://davidbecklab.org/

David B. Beck is an American physician-scientist, clinical geneticist, and researcher who co-discovered VEXAS Syndrome. [1] [2] [3] He holds dual appointments as an assistant professor in the Department of Medicine and the Department of Biochemistry and Molecular Pharmacology, and is a member of the Center for Human Genetics and Genomics and the Division of Rheumatology at New York University Grossman School of Medicine and NYU Langone Health. [4] [5]

Early life and education

David B. Beck was born in New Haven, Connecticut. He earned his Bachelor of Arts (BA) from Brown University. He would then go on to join the Medical Scientist Training Program (MSTP) at the New York University Grossman School of Medicine. Here he would earn both his PhD (2012) and M.D. (2014). [4] He completed his doctoral thesis in the laboratory of HHMI Investigator Danny Reinberg. [6] [7] Beck continued clinical training through the clinician scientist pathway in Internal Medicine at Columbia University and later went on to perform a fellowship in Clinical Genetics jointly at the National Institutes of Health and Johns Hopkins University School of Medicine combined program. [4]

Career

Following completion of his fellowship, Beck performed postdoctoral research with Daniel L. Kastner at the National Institutes of Health and National Human Genome Research Institute. During his training Beck and colleagues identified a novel inflammatory disorder they called vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic syndrome, or VEXAS syndrome. [1] [8] [9] In 2021, Beck joined the New York University Grossman School of Medicine faculty where he runs the Inflammatory Diseases Genetic Clinic and his own laboratory where he and his team investigate VEXAS syndrome as well as genetic causes of other disease, with an emphasis on inflammatory diseases and their underlying mechanisms. [10]

Related Research Articles

<span class="mw-page-title-main">Gene therapy</span> Medical field

Gene therapy is a medical field which focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material. The first attempt at modifying human DNA was performed in 1980, by Martin Cline, but the first successful nuclear gene transfer in humans, approved by the National Institutes of Health, was performed in May 1989. The first therapeutic use of gene transfer as well as the first direct insertion of human DNA into the nuclear genome was performed by French Anderson in a trial starting in September 1990. It is thought to be able to cure many genetic disorders or treat them over time.

Rheumatology is a branch of medicine devoted to the diagnosis and management of disorders whose common feature is inflammation in the bones, muscles, joints, and internal organs. Rheumatology covers more than 100 different complex diseases, collectively known as rheumatic diseases, which includes many forms of arthritis as well as lupus and Sjögren's syndrome. Doctors who have undergone formal training in rheumatology are called rheumatologists.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).

Rheumatism or rheumatic disorders are conditions causing chronic, often intermittent pain affecting the joints or connective tissue. Rheumatism does not designate any specific disorder, but covers at least 200 different conditions, including arthritis and "non-articular rheumatism", also known as "regional pain syndrome" or "soft tissue rheumatism". There is a close overlap between the term soft tissue disorder and rheumatism. Sometimes the term "soft tissue rheumatic disorders" is used to describe these conditions.

<span class="mw-page-title-main">Cold urticaria</span> Allergic reaction to low temperatures

Cold urticaria is a disorder in large red welts called hives (urticaria) form on the skin after exposure to a cold stimulus. The hives are usually itchy and often the hands and feet will become itchy and swollen as well. Hives vary in size from about 7 mm in diameter to as big as about 27 mm or larger.

<span class="mw-page-title-main">New York University Grossman School of Medicine</span> Medical school of New York University

NYU Grossman School of Medicine is a medical school of New York University, a private research university in New York City. It was founded in 1841 and is one of two medical schools of the university, with the other being the Long Island School of Medicine. NYU Grossman School of Medicine is part of NYU Langone Health, named after Kenneth Langone, the investment banker and financial backer of The Home Depot.

<span class="mw-page-title-main">Anakinra</span>

Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still's disease. It is a recombinant and slightly modified version of the human interleukin 1 receptor antagonist protein. It is marketed by Swedish Orphan Biovitrum. Anakinra is administered by subcutaneous injection.

<span class="mw-page-title-main">Relapsing polychondritis</span> Medical condition

Relapsing polychondritis is a multi-systemic condition characterized by repeated episodes of inflammation and deterioration of cartilage. The often painful disease can cause joint deformity and be life-threatening if the respiratory tract, heart valves, or blood vessels are affected. The exact mechanism is poorly understood, but it is thought to be related to an immune-mediated attack on particular proteins that are abundant in cartilage.

Periodic fever syndromes are a set of disorders characterized by recurrent episodes of systemic and organ-specific inflammation. Unlike autoimmune disorders such as systemic lupus erythematosus, in which the disease is caused by abnormalities of the adaptive immune system, people with autoinflammatory diseases do not produce autoantibodies or antigen-specific T or B cells. Instead, the autoinflammatory diseases are characterized by errors in the innate immune system.

<span class="mw-page-title-main">TNF receptor associated periodic syndrome</span> Medical condition

TNF receptor associated periodic syndrome (TRAPS) is a periodic fever syndrome associated with mutations in a receptor for the molecule tumor necrosis factor (TNF) that is inheritable in an autosomal dominant manner. Individuals with TRAPS have episodic symptoms such as recurrent high fevers, rash, abdominal pain, joint/muscle aches and puffy eyes.

<span class="mw-page-title-main">Canakinumab</span>

Canakinumab (INN), sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis (SJIA) and active Still's disease, including adult-onset Still's disease (AOSD). It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.

<span class="mw-page-title-main">NYU Langone Health</span> Hospital in New York, United States

NYU Langone Health is an academic medical center located in New York City, New York, United States. The health system consists of NYU Grossman School of Medicine and NYU Long Island School of Medicine, both part of New York University (NYU), and more than 300 locations throughout the New York metropolitan area, including six inpatient facilities: Tisch Hospital, Kimmel Pavilion, NYU Langone Orthopedic Hospital, Hassenfeld Children's Hospital, NYU Langone Hospital – Brooklyn and NYU Langone Hospital – Long Island. It is also home to Rusk Rehabilitation Institute.

<span class="mw-page-title-main">Lupus</span> Human autoimmune disease

Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.

<span class="mw-page-title-main">PAPA syndrome</span> Medical condition

PAPA syndrome is an acronym for pyogenic arthritis, pyoderma gangrenosum and acne. It is a rare genetic disorder characterised by its effects on skin and joints.

<span class="mw-page-title-main">Cryopyrin-associated periodic syndrome</span> Medical condition

Cryopyrin-associated periodic syndrome (CAPS) is a group of rare, heterogeneous autoinflammatory disease characterized by interleukin 1β-mediated systemic inflammation and clinical symptoms involving skin, joints, central nervous system, and eyes. It encompasses a spectrum of three clinically overlapping autoinflammatory syndromes including familial cold autoinflammatory syndrome, the Muckle–Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease that were originally thought to be distinct entities, but in fact share a single genetic mutation and pathogenic pathway, and keratoendotheliitis fugax hereditaria in which the autoinflammatory symptoms affect only the anterior segment of the eye.

<span class="mw-page-title-main">Multisystem inflammatory syndrome in children</span> Disease of children; pediatric comorbidity from COVID-19

Multisystem inflammatory syndrome in children (MIS-C), or paediatric inflammatory multisystem syndrome, or systemic inflammatory syndrome in COVID-19 (SISCoV), is a rare systemic illness involving persistent fever and extreme inflammation following exposure to SARS-CoV-2, the virus responsible for COVID-19. MIS-C has also been monitored as a potential, rare pediatric adverse event following COVID-19 vaccination. It can rapidly lead to medical emergencies such as insufficient blood flow around the body. Failure of one or more organs can occur. A warning sign is unexplained persistent fever with severe symptoms following exposure to COVID-19. Prompt referral to paediatric specialists is essential, and families need to seek urgent medical assistance. Most affected children will need intensive care.

VEXAS syndrome is an adult-onset autoinflammatory disease primarily affecting males, caused by a somatic mutation of the UBA1 gene in hematopoietic progenitor cells. The name VEXAS is an acronym deriving from the core features of disease:

<span class="mw-page-title-main">Daniel L. Kastner</span> American physician and researcher

Daniel L. Kastner is an American physician and researcher specialising in the genetics of autoinflammatory disorders. He is scientific director of the National Human Genome Research Institute, where he is a National Institutes of Health Distinguished Investigator. He was awarded the 2021 Crafoord Prize for Polyarthritis for his pioneering work on autoinflammatory diseases.

Autoinflammatory diseases (AIDs) are a group of rare disorders caused by dysfunction of the innate immune system. They are characterized by periodic or chronic systemic inflammation usually without the involvement of adaptive immunity.

References

  1. 1 2 Beck, David B.; Ferrada, Marcela A.; Sikora, Keith A.; Ombrello, Amanda K.; Collins, Jason C.; Pei, Wuhong; Balanda, Nicholas; Ross, Daron L.; Ospina Cardona, Daniela; Wu, Zhijie; Patel, Bhavisha (31 December 2020). "Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease". New England Journal of Medicine. 383 (27): 2628–2638. doi:10.1056/NEJMoa2026834. ISSN   0028-4793. PMC   7847551 . PMID   33108101.
  2. Marcela Ferrada, M. D. (2022-01-18). "VEXAS Syndrome". National Institute of Arthritis and Musculoskeletal and Skin Diseases. Retrieved 2023-01-20.
  3. Azvolinsky, Anna (24 January 2021). "The Vexing VEXAS Syndrome". American Society of Hematology Clinical News.
  4. 1 2 3 "Renowned Clinician-Scientist Joins Division of Rheumatology at NYU Langone Health". finance.yahoo.com. 18 October 2021. Retrieved 18 July 2022.
  5. Bammert, David (21 June 2022). "The Relapsing Polychondritis Foundation Invests in Potentially Groundbreaking Collaborative Research". polychondritis.org. Relapsing Polychondritis Foundation. Retrieved 19 July 2022.
  6. Reinberg, Danny (5 May 2014). "Past Students". reinberglab.com. Retrieved 18 July 2022.
  7. "Danny Reinberg". hhmi.org. Howard Hughes Medical Institute. 17 July 2022. Retrieved 19 July 2022.
  8. "New inflammatory disease discovered". National Institutes of Health (NIH). 2020-11-02. Retrieved 2022-07-18.
  9. Leslie, Mitch (23 September 2021). "This genetic sleuth has uncovered a new category of disease marked by sporadic fevers and inflammation". www.science.org. Retrieved 2022-10-18.
  10. Bammert, David (2022-03-31). "The Relapsing Polychondritis Foundation Invests in the Next Phase of VEXAS Research". The Relapsing Polychondritis Foundation. Retrieved 2022-07-18.